Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in Chronic Myeloid Leukemia patients of Kashmir

Publication date: September 2018Source: Meta Gene, Volume 17Author(s): Niyaz A. Azad, Zafar A. Shah, Arshad A. Pandith, Roohi Rasool, Javed A. Rasool, Shahid M. Baba, Sheikh A. Aziz, Samoon JeelaniAbstractThe phenomenon of imatinib resistance in Chronic Myeloid Leukemia (CML) can be mediated by “BCR-ABL fusion transcript dependent” and “BCR-ABL fusion transcript independent” pathways. The main means of “BCR-ABL fusion transcript dependent” pathway, responsible for 40–90% of such cases, is the occurrence of Kinase Domain (KD) mutations. The aim of this study was to evaluate the commonly occurring KD mutations like G250, Y253, E255, T315, F317, M351, F359, and H396 for imatinib resistance in CML patients from Kashmir (North India).A total of 42 confirmed cases of CML were subjected to reverse transcriptase polymerase chain reaction (RT-PCR). Kinase Domain PCR-amplicons, derived from the amplification of respective patient's cDNA following reverse transcription of BCR-ABL fusion mRNA, were subjected to nucleotide sequence analysis by ‘Genetic Analyser’ sequencing platform ABI 3500.CML patients included 18 males (42.85%) and 24 females (57.14%) aged from 7 to 75 years, of which 19 cases (45.23%) belonged to age group of ≤45 years and the rest 23 cases (54.76%) were>45 years of age. Sequence analysis was carried out to all the 42 patients at baseline and only on suspected resistant cases at designated follow-ups of 3 months, 6 months and one year.The ...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research